脑胶质瘤抗血管治疗现况与耐药机制研究进展  

Research progress on anti-angiogenic therapy and therapeutic resistance mechanism in glioma

作　　者：李卓群 张克难 陈婧 Li Zhuoqun;Zhang Kenan;Chen Jing(Beijing Neurosurgical Institute,Beijing 100070,China)

机构地区：[1]北京市神经外科研究所,100070

出　　处：《神经疾病与精神卫生》2024年第5期305-312,共8页Journal of Neuroscience and Mental Health

基　　金：国家自然科学基金(82103623)。

摘　　要：血管结构异常增生是各类实体肿瘤中的常见现象,在高级别脑胶质瘤中尤为显著。目前,已发现多种血管结构的形成机制,这些机制促进肿瘤内血管结构增殖,并在高级别胶质瘤中被验证。基于此机制,贝伐珠单抗被广泛应用于脑胶质瘤抗血管治疗,但仍面临诸多挑战,如贝伐珠单抗可提升患者的生活质量,延长患者无进展生存期,但是患者总体生存期无获益,且部分患者在治疗后无影像学改善,此外还存在耐药问题。既往研究认为耐药机制主要包括促进肿瘤细胞恶性表型进展和促进异常血管增生两种方式,可能为未来提高抗血管治疗效果、改善患者预后提供有效线索。Abnormal formation of blood vessels is a common phenomenon in various solid tumors,particularly prominent in high-grade glioma.Multiple mechanisms have been discovered for formation of blood vessels,which promote the angiogenesis within tumor tissues and have been validated in high-grade glioma.Bevacizumab has been widely used in anti-angiogenic therapy for glioma,however,anti-angiogenic therapy still faces many problems.For example,the use of bevacizumab can improve the quality of life of patients and prolong their progression free survival.However,the overall survival of patients is not beneficial,and some patients do not show any imaging improvement after treatment.In addition,the issue of resistance to bevacizumab remains unresolved.Previous studies have suggested that the therapeutic resistance mechanisms can be mainly divided into two ways of promoting the malignant phenotype progression of tumor cells and promoting abnormal formation of blood vessels.These therapeutic resistance mechanisms may provide clues for enhancing the effectiveness of anti-angiogenic therapy and improving patient prognosis in the future.

关 键 词：胶质瘤 血管生成 抗血管治疗 贝伐珠单抗 耐药机制 综述 

分 类 号：R739.41[医药卫生—肿瘤]